SCHEMBL417700

SCHEMBL417700

O=C(C=Cc1cccc(-c2cccc3cccnc23)c1)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 3/20 0.56
PPARG P37231 1/20 0.52
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 1/20 0.49
EGFR P00533 1/20 0.47
TRPA1 O75762 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
HDAC4 P56524 1/20 0.46
MEF2D Q14814 1/20 0.46
TRPM2 O94759 2/20 0.45
KDR P35968 1/20 0.45
KDM4E B2RXH2 2/20 0.45
RECQL P46063 2/20 0.45
MAPT P10636 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417699 1.00 SERPINE1 (0.56) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418644 0.99 SERPINE1 (0.55) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418645 0.91 SERPINE1 (0.69) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418643 0.91 SERPINE1 (0.69) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418363 0.90 SERPINE1 (0.54) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418364 0.90 SERPINE1 (0.54) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL417074 0.83 EGFR (0.62) SERPINE1NPC1RAB9ASMN1; SMN2EGFR
SCHEMBL417073 0.83 EGFR (0.62) SERPINE1NPC1RAB9ASMN1; SMN2EGFR
SCHEMBL422301 0.82 EGFR (0.51) SERPINE1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL422302 0.82 EGFR (0.51) SERPINE1NPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PPARG 3468/4885NPC1 2092/4885
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PPARG 2361/4885NPC1 893/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PPARG 2361/4885NPC1 893/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PPARG 2983/4885NPC1 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.